Cargando…
Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer
BACKGROUND: PI3K-Akt pathway activation and the expression of histone deacetylases (HDACs) are highly increased in esophageal cancer, suggesting that inhibition of such targets may be a viable therapeutic strategy. Herein, we aimed to evaluate the anti-tumor effect of CUDC-907, a dual PI3K-HDAC inhi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394063/ https://www.ncbi.nlm.nih.gov/pubmed/35989326 http://dx.doi.org/10.1186/s13578-022-00855-x |
_version_ | 1784771407210610688 |
---|---|
author | Jian, Zheng Han, Yichao Zhang, Wentian Li, Chengqiang Guo, Wei Feng, Xijia Li, Bin Li, Hecheng |
author_facet | Jian, Zheng Han, Yichao Zhang, Wentian Li, Chengqiang Guo, Wei Feng, Xijia Li, Bin Li, Hecheng |
author_sort | Jian, Zheng |
collection | PubMed |
description | BACKGROUND: PI3K-Akt pathway activation and the expression of histone deacetylases (HDACs) are highly increased in esophageal cancer, suggesting that inhibition of such targets may be a viable therapeutic strategy. Herein, we aimed to evaluate the anti-tumor effect of CUDC-907, a dual PI3K-HDAC inhibitor, in esophageal squamous cell carcinoma (ESCC). METHODS: The anti-tumor effects of CUDC-907 in ESCC were evaluated using cell counting kit-8, flow cytometry, and western blot. mRNA-sequencing was used to explore the mechanism underlying CUDC-907 anti-tumor effects. The relations of reactive oxygen species (ROS), lipocalin 2 (LCN2), and CUDC-907 were determined by flow cytometry, rescue experiments, and western blot. The activation of the IRE1α-JNK-CHOP signal cascade was confirmed by western blot. The in vivo inhibitory effects of CUDC-907 were examined by a subcutaneous xenograft model in nude mice. RESULTS: CUDC-907 displayed effective inhibition in the proliferation, migration, and invasion of ESCC cells. Through an mRNA-sequencing and functional enrichment analysis, autophagy was found to be associated with cancer cells death. CUDC-907 not only inhibited the PI3K-Akt-mTOR pathways to result in autophagy, but also induced ROS accumulation to activate IRE1α-JNK-CHOP-mediated cytotoxic autophagy by downregulating LCN2 expression. Consistently, the in vivo anti-tumor effects of CUDC-907 accompanied by the downregulated expression of p-mTOR and LCN2 and upregulated expression of p-IRE1α and LC3B-II were evaluated in a xenograft mouse model. CONCLUSION: Our findings suggested the clinical development and administration of CUDC-907 might act as a novel treatment strategy for ESCC. A more in-depth understanding of the anti-tumor effect of CUDC-907 in ESCC will benefit the clinically targeted treatment of ESCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00855-x. |
format | Online Article Text |
id | pubmed-9394063 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-93940632022-08-23 Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer Jian, Zheng Han, Yichao Zhang, Wentian Li, Chengqiang Guo, Wei Feng, Xijia Li, Bin Li, Hecheng Cell Biosci Research BACKGROUND: PI3K-Akt pathway activation and the expression of histone deacetylases (HDACs) are highly increased in esophageal cancer, suggesting that inhibition of such targets may be a viable therapeutic strategy. Herein, we aimed to evaluate the anti-tumor effect of CUDC-907, a dual PI3K-HDAC inhibitor, in esophageal squamous cell carcinoma (ESCC). METHODS: The anti-tumor effects of CUDC-907 in ESCC were evaluated using cell counting kit-8, flow cytometry, and western blot. mRNA-sequencing was used to explore the mechanism underlying CUDC-907 anti-tumor effects. The relations of reactive oxygen species (ROS), lipocalin 2 (LCN2), and CUDC-907 were determined by flow cytometry, rescue experiments, and western blot. The activation of the IRE1α-JNK-CHOP signal cascade was confirmed by western blot. The in vivo inhibitory effects of CUDC-907 were examined by a subcutaneous xenograft model in nude mice. RESULTS: CUDC-907 displayed effective inhibition in the proliferation, migration, and invasion of ESCC cells. Through an mRNA-sequencing and functional enrichment analysis, autophagy was found to be associated with cancer cells death. CUDC-907 not only inhibited the PI3K-Akt-mTOR pathways to result in autophagy, but also induced ROS accumulation to activate IRE1α-JNK-CHOP-mediated cytotoxic autophagy by downregulating LCN2 expression. Consistently, the in vivo anti-tumor effects of CUDC-907 accompanied by the downregulated expression of p-mTOR and LCN2 and upregulated expression of p-IRE1α and LC3B-II were evaluated in a xenograft mouse model. CONCLUSION: Our findings suggested the clinical development and administration of CUDC-907 might act as a novel treatment strategy for ESCC. A more in-depth understanding of the anti-tumor effect of CUDC-907 in ESCC will benefit the clinically targeted treatment of ESCC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00855-x. BioMed Central 2022-08-21 /pmc/articles/PMC9394063/ /pubmed/35989326 http://dx.doi.org/10.1186/s13578-022-00855-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Jian, Zheng Han, Yichao Zhang, Wentian Li, Chengqiang Guo, Wei Feng, Xijia Li, Bin Li, Hecheng Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title | Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title_full | Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title_fullStr | Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title_full_unstemmed | Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title_short | Anti-tumor effects of dual PI3K-HDAC inhibitor CUDC-907 on activation of ROS-IRE1α-JNK-mediated cytotoxic autophagy in esophageal cancer |
title_sort | anti-tumor effects of dual pi3k-hdac inhibitor cudc-907 on activation of ros-ire1α-jnk-mediated cytotoxic autophagy in esophageal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394063/ https://www.ncbi.nlm.nih.gov/pubmed/35989326 http://dx.doi.org/10.1186/s13578-022-00855-x |
work_keys_str_mv | AT jianzheng antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT hanyichao antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT zhangwentian antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT lichengqiang antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT guowei antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT fengxijia antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT libin antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer AT lihecheng antitumoreffectsofdualpi3khdacinhibitorcudc907onactivationofrosire1ajnkmediatedcytotoxicautophagyinesophagealcancer |